WR-2721 inhibition of radiation-induced prostaglandin excretion in rats.
Pre-irradiation administration of the radioprotectant drug WR-2721 to rats resulted in a significant reduction in radiation-induced increases in excretion rates of prostaglandins (PGE and PGF2 alpha) and thromboxane (TxB2). In animals not irradiated. WR-2721 did not significantly alter these excretion rates. Dramatic reductions in the levels of urinary PGE and TxB2 were observed following exposure to 9.0 Gy of whole-body, unilateral gamma-radiation in WR-2721-treated animals, whereas changes in PGF2 alpha levels were less pronounced. Radiation-induced diuresis was also significantly depressed in animals given WR-2721 before irradiation. Reduced prostaglandin excretion rates may reflect the general radioprotective capacity of the chemoprotector WR-2721 on the release of prostaglandins from radiation-damaged tissue. The decrease in diuresis may be related to the observed prostaglandin decreases.
Donlon
M
M
Steel
L
L
Helgeson
E A
EA
Wolfe
W W
WW
Catravas
G N
GN
D004999:Amifostine / Q000494:pharmacology*; D000818:Animals; D003037:Cobalt Radioisotopes; D015237:Dinoprost; D005720:Gamma Rays; D008297:Male; D009946:Organothiophosphorus Compounds / Q000494:pharmacology*; D011453:Prostaglandins / Q000652:urine*; D011458:Prostaglandins E / Q000652:urine; D011460:Prostaglandins F / Q000652:urine; D011833:Radiation Injuries, Experimental / Q000652:urine*; D011837:Radiation-Protective Agents / Q000494:pharmacology*; D051381:Rats; D011919:Rats, Inbred Strains; D013929:Thromboxane B2 / Q000652:urine
D003037:Cobalt Radioisotopes; D009946:Organothiophosphorus Compounds; D011453:Prostaglandins; D011458:Prostaglandins E; D011460:Prostaglandins F; D011837:Radiation-Protective Agents; D013929:Thromboxane B2; D015237:Dinoprost; D004999:Amifostine